An observational study in Extranodal NK/T-cell Lymphoma, Nasal Type, sponsored by Fujian Medical University Union Hospital. Active, not recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Fujian Medical University Union Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China — 22 open to participants now, 25 under way, 2 of them phase 3. Lymphoma, Extranodal NK-T-Cell · China.
Among the 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China, this one is one of 4 that started in 2022, is one of 7 observational ones, reaches primary completion later than 18 of the 24 other live ones, and was the 73rd registered.
270 studies on the registry are indexed under Lymphoma, Extranodal NK-T-Cell; 36 are open to participants now.
Browse Lymphoma, Extranodal NK-T-Cell studies →22 of the 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China are open now. Recruiting first, the newest first:
Rong Tao · Sites in China
Ages 18–70
Rong Tao · Sites in China
Ages 18+
Rong Tao · Sites in China
Ages 18+
Beijing Tongren Hospital · Sites in China
Ages 18+
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 20 Lymphoma, Extranodal NK-T-Cell studies recruiting now, 11 (55%) set no upper age limit and 8 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 43 · Phase 3 5 · Phase 4 5
First in 2007; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 54 across 25 observational studies indexed under Lymphoma, Extranodal NK-T-Cell.
Median enrollment 40 across the 65 interventional studies, 665 across the 7 observational. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 73 have an industry lead sponsor. The 10 most frequent:
Fujian Medical University Union Hospital is the lead sponsor of 109 studies on the registry; 79 are open to participants now.
Fujian Medical University Union Hospital has 1 study filed under Lymphoma, Extranodal NK-T-Cell — fewer than ten, so there is no comparison to draw.
3 of the studies in Lymphoma, Extranodal NK-T-Cell with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04417166International Extranodal Lymphoma Study Group (IELSG)Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma | 2026-12 |
| NCT07000617Peking University Cancer Hospital & InstituteA Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma | 2026-12 |
| NCT06732492Wuhan Union Hospital, ChinaRD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 73 studies in Lymphoma, Extranodal NK-T-Cell with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This retrospective observational study characterises the tumour immune microenvironment and clonal architecture of relapsed or refractory extranodal NK/T-cell lymphoma (ENKTCL). Archival tumour tissue and blood samples collected during routine care are profiled by single-cell RNA sequencing, T-cell and B-cell receptor repertoire sequencing, whole-exome sequencing, and spatial transcriptomics. The study examines how immune and stromal cell states, clonal composition and spatial organisation relate to response to programmed cell death protein 1 (PD-1) blockade and to subsequent relapse.
Extranodal NK/T-cell lymphoma is an Epstein-Barr virus (EBV)-associated lymphoma with a high relapse rate and few validated molecular predictors of response to immune checkpoint blockade. In this retrospective study, we assemble a cohort of patients with relapsed or refractory ENKTCL treated at a single centre, with a planned total of up to 50 patients, together with available pre- and post-treatment tumour tissue and peripheral blood. Samples are analysed by single-cell RNA sequencing with paired T-cell receptor (TCR) and B-cell receptor (BCR) repertoire sequencing, whole-exome sequencing, multiplex imaging, and spatial transcriptomics where tissue permits. We characterise the composition and transcriptional states of immune and stromal populations, the genomic landscape including chromosome 6q loss, the relationship between clonal architecture and spatial organisation, and the association of these features with response to PD-1 blockade and with relapse patterns. Analyses are descriptive and hypothesis-generating; no intervention, treatment assignment or change in clinical care is involved. All analyses are covered by approvals from the Ethics Committee of Fujian Medical University Union Hospital (2022WSJK019, approved 27 September 2022; 2023KY146, approved 22 August 2023).
Patients with extranodal NK/T-cell lymphoma treated at Fujian Medical University Union Hospital, China, whose archival tumour tissue and peripheral blood samples are available for molecular profiling.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who achieved an objective response to PD-1 or PD-L1 blockade, from whom pre- and post-treatment tumour tissue and peripheral blood were profiled.
Patients who did not achieve an objective response to PD-1 or PD-L1 blockade, from whom pre- and post-treatment tumour tissue and peripheral blood were profiled.
Composition and transcriptional states of immune and stromal cell populations in ENKTCL tumour tissue
Cell-type composition, activation and exhaustion states of T, NK, B and myeloid populations and of stromal subsets, determined by single-cell RNA sequencing of tumour tissue.
Time frame: Baseline (pre-treatment) and relapse (up to 36 months after diagnosis); assessed retrospectively
Clonal architecture of T-cell and B-cell receptor repertoires
Clonal diversity and the distribution of expanded clones across transcriptional cell states, determined by paired T-cell and B-cell receptor repertoire sequencing.
Time frame: Baseline and relapse (up to 36 months after diagnosis); assessed retrospectively
Somatic genomic alterations, including chromosome 6q copy-number loss
Somatic mutations and copy-number alterations determined by whole-exome sequencing of tumour tissue.
Time frame: Baseline, assessed retrospectively
Spatial organisation of tumour and immune compartments
Spatial distribution of malignant, immune and stromal compartments in archival tissue, determined by spatial transcriptomics and multiplex imaging.
Time frame: Baseline and relapse (up to 36 months after diagnosis); assessed retrospectively
Correlation of baseline immune and stromal features with response to PD-1 or PD-L1 blockade
Correlation between baseline immune and stromal features in tumour tissue, expressed as the percentage of cluster of differentiation 8 (CD8)-positive T cells, NK cells, B cells and plasma cells among all cells and as their spatial density (cells per mm2), measured by single-cell RNA sequencing and spatial transcriptomics; and objective response to PD-1 or PD-L1 blockade, expressed as the percentage of patients achieving a complete or partial response by RECIST 1.1 or LYRIC criteria.
Time frame: Baseline (pre-treatment) through study completion, an average of 36 months
Correlation of baseline immune and stromal features with relapse site and pattern
Correlation between baseline immune and stromal features in tumour tissue, expressed as the percentage of T cells, NK cells, B cells and plasma cells among all cells, measured by single-cell RNA sequencing; and relapse site and pattern, expressed as the percentage of patients with local, regional or distant relapse classified from imaging and clinical records.
Time frame: Baseline (pre-treatment) through study completion, an average of 36 months
Plan to share: No — Individual participant data, including clinical records and sample-level identifiers, will not be shared. De-identified sequencing and spatial transcriptomic data will be deposited in the Genome Sequence Archive for Human (GSA-Human), National Genomics Data Center, China, and will be made available for research use through the repository according to its access policy after publication.
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Dec 2028, 75 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoma, Extranodal NK-T-Cell →
Fujian Medical University Union Hospital →